CL2007002851A1 - Composicion inyectable que comprende micro o nano -particulas biodegradables que incluyen un agente activo, un polimero biodegardable, un agente para intensificar la viscosidad y excipiente farmaceuticamente aceptables; y procedimientos de preparacion - Google Patents
Composicion inyectable que comprende micro o nano -particulas biodegradables que incluyen un agente activo, un polimero biodegardable, un agente para intensificar la viscosidad y excipiente farmaceuticamente aceptables; y procedimientos de preparacionInfo
- Publication number
- CL2007002851A1 CL2007002851A1 CL2007002851A CL2007002851A CL2007002851A1 CL 2007002851 A1 CL2007002851 A1 CL 2007002851A1 CL 2007002851 A CL2007002851 A CL 2007002851A CL 2007002851 A CL2007002851 A CL 2007002851A CL 2007002851 A1 CL2007002851 A1 CL 2007002851A1
- Authority
- CL
- Chile
- Prior art keywords
- agent
- micro
- nanodegradable
- intensifying
- excipient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composición inyectable que comprende ingredientes activos o sus sales, derivados, isomeros, polimorfos, solvatos, hidratos o sus mezclas, polímeros biodegradables, agentes aumentadores de viscosidad, composición que se formula como micro o nano-partículas; procedimiento para la preparación de dicha composición; y kit farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2195DE2006 | 2006-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002851A1 true CL2007002851A1 (es) | 2008-01-18 |
Family
ID=39268891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2007002851A CL2007002851A1 (es) | 2006-10-05 | 2007-10-03 | Composicion inyectable que comprende micro o nano -particulas biodegradables que incluyen un agente activo, un polimero biodegardable, un agente para intensificar la viscosidad y excipiente farmaceuticamente aceptables; y procedimientos de preparacion |
Country Status (17)
Country | Link |
---|---|
US (2) | US20100015195A1 (es) |
EP (2) | EP2086505A2 (es) |
JP (2) | JP2010505821A (es) |
KR (2) | KR20090094811A (es) |
CN (2) | CN101541316A (es) |
AR (1) | AR063120A1 (es) |
AU (2) | AU2007303793A1 (es) |
BR (2) | BRPI0718288A2 (es) |
CA (2) | CA2665105A1 (es) |
CL (1) | CL2007002851A1 (es) |
EA (1) | EA200970348A1 (es) |
IL (2) | IL197947A0 (es) |
MA (2) | MA30814B1 (es) |
MX (2) | MX2009003735A (es) |
RU (1) | RU2009116933A (es) |
TN (2) | TN2009000124A1 (es) |
WO (2) | WO2008041246A2 (es) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
DK2526996T3 (da) * | 2002-12-20 | 2019-12-02 | Xeris Pharmaceuticals Inc | Formulering til intrakutan injektion |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US9205046B2 (en) * | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Enhanced stability of inverse thermal gelling composite hydrogels |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
KR20100023862A (ko) * | 2007-06-22 | 2010-03-04 | 싸이도우스 엘엘씨. | 트윈 80을 함유하지 않은 도세탁셀의 용해 제제 |
US10632079B2 (en) * | 2007-06-25 | 2020-04-28 | Otsuka Pharmaceuticals Co., Ltd. | Microspheres having core/shell structure |
CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
KR20100121505A (ko) * | 2008-03-07 | 2010-11-17 | 싸이도우스 엘엘씨. | 플배스트랜 제제 |
US8524267B2 (en) * | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
CN101569622B (zh) * | 2008-04-30 | 2012-11-21 | 天津药物研究院 | 一种用于注射给药的药物制剂及其制备方法 |
EA014044B1 (ru) * | 2008-07-09 | 2010-08-30 | Общество С Ограниченной Ответственностью "Аква-Альянс" | Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты) |
CN104248623B (zh) * | 2008-09-04 | 2020-04-03 | 安米林药品有限责任公司 | 使用非水性载体的持续释放制剂 |
CN102281870B (zh) | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
US8673264B2 (en) | 2009-03-02 | 2014-03-18 | Assistance Publique-Hopitaux De Paris | Injectable biomaterial |
WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
CN101669942A (zh) * | 2009-09-29 | 2010-03-17 | 北京华禧联合科技发展有限公司 | 难溶性药物组合物 |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
US8476310B2 (en) | 2009-10-19 | 2013-07-02 | Scidose Llc | Docetaxel formulations with lipoic acid |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US9504698B2 (en) * | 2009-10-29 | 2016-11-29 | Warsaw Orthopedic, Inc. | Flowable composition that sets to a substantially non-flowable state |
RU2548753C2 (ru) | 2009-11-16 | 2015-04-20 | Ипсен Фарма С.А.С. | Фармацевтические композиции лигандов рецепторов меланокортинов |
EP2547351B1 (en) * | 2010-03-15 | 2016-04-27 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of growth hormone secretagogue receptor ligands |
US9504643B2 (en) * | 2010-03-29 | 2016-11-29 | Evonik Corporation | Compositions and methods for improved retention of a pharmaceutical composition at a local administration site |
US10350159B2 (en) * | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
ES2390439B1 (es) | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
DE102010023949A1 (de) * | 2010-06-16 | 2011-12-22 | F. Holzer Gmbh | In-situ Lecithin-Mikroemulsionsgel-Formulierung |
US20120046225A1 (en) | 2010-07-19 | 2012-02-23 | The Regents Of The University Of Colorado, A Body Corporate | Stable glucagon formulations for the treatment of hypoglycemia |
AR082494A1 (es) * | 2010-08-24 | 2012-12-12 | Otsuka Pharma Co Ltd | Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona |
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
AU2011320758B2 (en) * | 2010-10-28 | 2015-09-24 | Alpha To Omega Pharmaceutical Consultants, Inc. | Aripiprazole compositions and methods for its transdermal delivery |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CN105853348B (zh) | 2011-03-10 | 2019-08-30 | Xeris药物公司 | 肠胃外注射用稳定溶液 |
HRP20240285T1 (hr) * | 2011-03-18 | 2024-05-24 | Alkermes Pharma Ireland Limited | Farmaceutski pripravci koji sadrže sorbitan estere |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
WO2013067022A1 (en) | 2011-10-31 | 2013-05-10 | Xeris Pharmaceuticals, Inc. | Formulations for the treatment of diabetes |
US11179468B2 (en) | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
EP2705835A1 (en) * | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
CN103483353B (zh) * | 2012-06-13 | 2016-02-24 | 上海现代药物制剂工程研究中心有限公司 | 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法 |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
KR101811797B1 (ko) * | 2013-04-03 | 2017-12-22 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
US9949928B2 (en) * | 2013-05-01 | 2018-04-24 | The Regents Of The University Of Colorado, A Body Corporate | Biodegradable copolymers, systems including the copolymers, and methods of forming and using same |
EP3063218A4 (en) * | 2013-08-22 | 2017-07-26 | Polyvalor, Limited Partnership | Porous gels and methods for their preparation |
JP2015093854A (ja) * | 2013-11-12 | 2015-05-18 | 株式会社クレハ | 水性組成物および加水分解抑制方法 |
CH708890B1 (de) * | 2013-11-22 | 2018-03-15 | Sandel Thomas | Ball, vorzugsweise Golfball, sowie ein mit dem Ball kommunizierbares elektronisches Gerät. |
US20150174254A1 (en) | 2013-12-23 | 2015-06-25 | Mcneil-Ppc, Inc. | Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
KR102428675B1 (ko) | 2014-08-06 | 2022-08-02 | 엑스에리스 파머수티클스, 인크. | 페이스트의 피내 및/또는 피하 주사를 위한 주사기, 키트, 및 방법 |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3217959A1 (en) * | 2014-11-10 | 2017-09-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long acting pharmaceutical compositions for hepatitis c |
EP3028721A1 (en) * | 2014-12-05 | 2016-06-08 | Exchange Imaging Technologies GmbH | Nanoparticle formulation having reverse-thermal gelation properties for injection |
KR101692314B1 (ko) * | 2015-03-27 | 2017-01-03 | 주식회사 주빅 | 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템 |
US9844558B1 (en) | 2015-04-30 | 2017-12-19 | Amag Pharmaceuticals, Inc. | Methods of reducing risk of preterm birth |
MA44390A (fr) | 2015-06-03 | 2019-01-23 | Intarcia Therapeutics Inc | Systèmes de mise en place et de retrait d'implant |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US20170128424A1 (en) * | 2015-11-11 | 2017-05-11 | Qrono, Inc. | Sustained release pharmaceutical compositions and methods of use |
WO2017105512A1 (en) * | 2015-12-18 | 2017-06-22 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
SG11201810102SA (en) | 2016-05-16 | 2018-12-28 | Intarcia Therapeutics Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
WO2017200987A1 (en) * | 2016-05-16 | 2017-11-23 | Amag Pharmaceuticals, Inc. | Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
WO2018015915A1 (en) * | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
KR20190101408A (ko) * | 2017-01-23 | 2019-08-30 | 세이비어 라이프텍 코퍼레이션 | 활성 성분의 미립자 제조 |
CN106822042A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 一种利培酮缓释组合物及其制备方法 |
CN106822043A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 利培酮缓释组合物及其制备方法 |
CN116270486A (zh) * | 2017-01-24 | 2023-06-23 | 广州帝奇医药技术有限公司 | 水难溶或微溶性药物缓释组合物及其制备方法 |
CN106727422B (zh) * | 2017-03-09 | 2018-10-02 | 王秋玉 | 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用 |
EP4378463A2 (en) | 2017-06-02 | 2024-06-05 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
SG11202002105WA (en) | 2017-09-11 | 2020-04-29 | Atossa Therapeutics Inc | Methods for making and using endoxifen |
GB2568370B (en) | 2017-09-15 | 2020-09-30 | Oxular Ltd | Ophthalmic delivery device |
US10912762B2 (en) * | 2018-03-23 | 2021-02-09 | Laboratoires Major | Non-hormonal compositions and methods for male contraception |
PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
WO2020256340A2 (ko) * | 2019-06-21 | 2020-12-24 | 고려대학교산학협력단 | 체내 부피 유지 제제, 이를 포함하는 주사제 및 이의 제조방법 |
CN111388744B (zh) * | 2020-01-15 | 2021-05-18 | 华中科技大学 | 一种凝胶贮库及其制法与制备术后止血制剂的应用 |
CN111956599B (zh) * | 2020-09-29 | 2023-02-17 | 江苏集萃新型药物制剂技术研究所有限公司 | 皮下植入药剂及其组合物和制备方法 |
KR102266384B1 (ko) * | 2021-01-25 | 2021-06-21 | 주식회사 울트라브이 | 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제 |
KR102652905B1 (ko) * | 2021-08-09 | 2024-04-01 | 주식회사 메디폴리머 | 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트 |
TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
CN116850146B (zh) * | 2023-05-22 | 2024-05-14 | 济南大学 | 伏硫西汀自由碱或其药用盐长效缓释制剂及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242910A (en) * | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
PT669128E (pt) * | 1992-11-17 | 2000-06-30 | Yoshitomi Pharmaceutical | Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma |
US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
GB9718986D0 (en) * | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
CA2435415A1 (en) * | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
US7691412B2 (en) * | 2001-10-10 | 2010-04-06 | Pierre Fabre Medicament | Prolonged release biodegradable microspheres and method for preparing same |
TW200719903A (en) * | 2005-04-19 | 2007-06-01 | Combinatorx Inc | Compositions for the treatment of neoplasms |
-
2007
- 2007-10-03 KR KR1020097009289A patent/KR20090094811A/ko active IP Right Grant
- 2007-10-03 MX MX2009003735A patent/MX2009003735A/es unknown
- 2007-10-03 CN CNA2007800441356A patent/CN101541316A/zh active Pending
- 2007-10-03 WO PCT/IN2007/000473 patent/WO2008041246A2/en active Application Filing
- 2007-10-03 JP JP2009531016A patent/JP2010505821A/ja not_active Withdrawn
- 2007-10-03 BR BRPI0718288-0A2A patent/BRPI0718288A2/pt not_active Application Discontinuation
- 2007-10-03 US US12/444,197 patent/US20100015195A1/en not_active Abandoned
- 2007-10-03 CL CL2007002851A patent/CL2007002851A1/es unknown
- 2007-10-03 CN CNA2007800441089A patent/CN101541313A/zh active Pending
- 2007-10-03 MX MX2009003737A patent/MX2009003737A/es not_active Application Discontinuation
- 2007-10-03 EP EP07827598A patent/EP2086505A2/en not_active Withdrawn
- 2007-10-03 KR KR1020097009284A patent/KR20090087441A/ko not_active Application Discontinuation
- 2007-10-03 US US12/444,257 patent/US20100098735A1/en not_active Abandoned
- 2007-10-03 CA CA002665105A patent/CA2665105A1/en not_active Abandoned
- 2007-10-03 RU RU2009116933/15A patent/RU2009116933A/ru not_active Application Discontinuation
- 2007-10-03 EA EA200970348A patent/EA200970348A1/ru unknown
- 2007-10-03 WO PCT/IN2007/000454 patent/WO2008041245A2/en active Application Filing
- 2007-10-03 AU AU2007303793A patent/AU2007303793A1/en not_active Abandoned
- 2007-10-03 CA CA002665101A patent/CA2665101A1/en not_active Abandoned
- 2007-10-03 JP JP2009531014A patent/JP2010505819A/ja not_active Withdrawn
- 2007-10-03 AR ARP070104388A patent/AR063120A1/es unknown
- 2007-10-03 BR BRPI0720346-2A2A patent/BRPI0720346A2/pt not_active IP Right Cessation
- 2007-10-03 EP EP07827594A patent/EP2089000A2/en not_active Withdrawn
- 2007-10-03 AU AU2007303794A patent/AU2007303794A1/en not_active Abandoned
-
2009
- 2009-04-03 TN TNP2009000124A patent/TN2009000124A1/fr unknown
- 2009-04-03 TN TNP2009000125A patent/TN2009000125A1/fr unknown
- 2009-04-05 IL IL197947A patent/IL197947A0/en unknown
- 2009-04-05 IL IL197946A patent/IL197946A0/en unknown
- 2009-04-27 MA MA31821A patent/MA30814B1/fr unknown
- 2009-04-27 MA MA31824A patent/MA30817B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20100098735A1 (en) | 2010-04-22 |
JP2010505821A (ja) | 2010-02-25 |
KR20090094811A (ko) | 2009-09-08 |
CA2665101A1 (en) | 2008-04-10 |
WO2008041245A2 (en) | 2008-04-10 |
EP2086505A2 (en) | 2009-08-12 |
EA200970348A1 (ru) | 2009-10-30 |
TN2009000125A1 (en) | 2010-10-18 |
IL197947A0 (en) | 2009-12-24 |
AR063120A1 (es) | 2008-12-30 |
AU2007303794A1 (en) | 2008-04-10 |
AU2007303793A1 (en) | 2008-04-10 |
TN2009000124A1 (en) | 2010-10-18 |
CA2665105A1 (en) | 2008-04-10 |
RU2009116933A (ru) | 2010-11-10 |
MA30814B1 (fr) | 2009-10-01 |
BRPI0718288A2 (pt) | 2013-11-19 |
KR20090087441A (ko) | 2009-08-17 |
CN101541316A (zh) | 2009-09-23 |
EP2089000A2 (en) | 2009-08-19 |
MX2009003735A (es) | 2009-04-22 |
US20100015195A1 (en) | 2010-01-21 |
WO2008041246A2 (en) | 2008-04-10 |
WO2008041245A3 (en) | 2008-05-22 |
WO2008041246A3 (en) | 2008-05-29 |
MA30817B1 (fr) | 2009-10-01 |
IL197946A0 (en) | 2009-12-24 |
JP2010505819A (ja) | 2010-02-25 |
BRPI0720346A2 (pt) | 2014-06-24 |
CN101541313A (zh) | 2009-09-23 |
MX2009003737A (es) | 2009-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002851A1 (es) | Composicion inyectable que comprende micro o nano -particulas biodegradables que incluyen un agente activo, un polimero biodegardable, un agente para intensificar la viscosidad y excipiente farmaceuticamente aceptables; y procedimientos de preparacion | |
ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
CY1121729T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων | |
AR082826A2 (es) | Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos | |
CY1117143T1 (el) | Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης | |
UY31481A1 (es) | Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones | |
CY1116688T1 (el) | Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων | |
CY1118541T1 (el) | D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης | |
UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
UY30976A1 (es) | Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones. | |
UY30748A1 (es) | Compuesto0s novedosos | |
CO6361937A2 (es) | Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa | |
UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
UY31524A1 (es) | Nuevos compuestos 010 | |
CL2008001301A1 (es) | Compuestos derivados de heterociclos de nitrogeno; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una condicion inflamatoria o alergica, tal como una enfermedad inflamatoria u obstructiva de las vias respiratorias mediada por el bloqueo del canal de sodio epitelial. | |
CR10875A (es) | Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides | |
DOP2010000387A (es) | Compuestos pirazolicos 436 | |
UY30789A1 (es) | Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
CR20110592A (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
UY30641A1 (es) | Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones | |
BR112012033391A8 (pt) | kit contraceptivo, método contraceptivo para uma paciente do sexo feminino necessitando do mesmo e composição farmacêutica compreendendo drospirenova. | |
UY29360A1 (es) | Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones. |